Compositions and Methods for Inhibition of Pathogenic Bacterial Growth
AssigneeSeres Therapeutics, Inc.
InventorsDavid N. Cook, Han Zhang, Anthony Mario D'Onofrio, David Arthur Berry, Mary-Jane Lombardo McKenzie, John Grant Aunins, Gregory McKenzie, Toshiro K. Ohsumi
Life of this patent
Estimating the term…
Abstract
Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.
Claims22
A composition comprising an effective amount of a first type of bacteria and a second type of bacteria formulated for oral administration to a mammalian subject, wherein the first and second type of bacteria are:
- (i) isolated, (ii) not identical, and (iii) independently capable of proliferating in a nutrient medium having a threshold concentration of a nutrient below that concentration required for Clostridium difficile proliferation.
A composition comprising an effective amount of a first type of bacteria and a second type of bacteria that are independently capable of proliferating at a rate at least 10% greater than Clostridium difficile in a nutrient medium having a limiting concentration of one or more essential carbohydrate nutrients.
-25. (canceled)
A method for the treatment of Clostridium difficile infection in a mammalian subject, comprising the step of orally administering to the subject a composition comprising an effective amount of a first type of bacteria and a second type of bacteria formulated for oral administration to a mammalian subject, wherein the first type of bacteria is:
- (i) isolated, (ii) not identical to the second type of bacteria, and (iii) independently capable of saccharification at a rate at least 10% greater than Clostridium difficile, and wherein the second type of bacteria is:
- (i) isolated, (ii) not identical to the first type of bacteria, and (iii) independently capable of glycolysis of a nutrient selected from the group consisting of glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuramic acid (NAN), at a rate at least 10% greater than Clostridium difficile or at a concentration at least 10% less than Clostridium difficile, or the combination thereof, under conditions such that the first type of bacteria and the second type of bacteria functionally populate the gastrointestinal tract of the subject and prevent the population of the gastrointestinal tract by Clostridium difficile.
-46. (canceled)
Dependencies are inferred from the claim text.